Dr. Grunwald on the Efficacy of 19-28z CAR T-Cell Therapy in B-ALL

Video

Michael R. Grunwald, MD, FACP, discusses the efficacy of 19-28z CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

Michael R. Grunwald, MD, FACP, clinical assistant professor of medicine, University of North Carolina, hematologist/oncologist, Levine Cancer Institute, Atrium Health, discusses the efficacy of 19-28z CAR T-cell therapy in B-cell acute lymphoblastic leukemia (B-ALL).

Long-term follow-up results of a phase 1 trial (NCT01044069) demonstrated a median overall survival of 12.9 months with 19-28z CAR T-cell therapy in adult patients with relapsed/refractory B-ALL, says Grunwald.

Overall, 53 patients with heavily pretreated disease received the 19-28z CAR T-cell therapy. Nineteen of these patients (36%) had undergone prior allogeneic hematopoietic stem cell transplant and 13 (25%) received prior blinatumomab (Blincyto), Grunwald explains. Patients were a median of 44 years old (range, 23-74), adds Grunwald.

Regarding efficacy, 83% of patients achieved a complete remission with 19-28z CAR T-cell therapy, says Grunwald. Some modifications were made during the study treatment with the goal of reducing CAR T-cell therapy–related toxicities, such as cytokine release syndrome, Grunwald says. Fractionating the doses of cells may reduce the rate of toxicity in adults; however, the promising efficacy signal suggests that this therapy should be evaluated further in patients with relapsed/refractory B-ALL, concludes Grunwald.

Related Videos
Brian Van Tine, MD, PhD, on Looking Ahead on Cell Therapy for Sarcomas
Dilsher Dhoot, MD, on a Promising Start With Diabetic Retinopathy Gene Therapy RGX-314
J. Andrew Livingston, MD, on Forging Forward With Novel Sarcoma Trials
Shankar Musunuri, PhD, on Gene Modifier Therapy vs Gene Replacement Therapy for IRDs
Pat Furlong, BSN, RN, on the State of Gene Therapy in Muscular Dystrophy
Michael Kelly, PhD, on Continuing Progress With Gene Therapy in Muscular Dystrophy
© 2023 MJH Life Sciences

All rights reserved.